Clinical Trials Logo

Intrahepatic Cholangiocarcinoma clinical trials

View clinical trials related to Intrahepatic Cholangiocarcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05292443 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Start date: December 20, 2021
Phase:
Study type: Observational [Patient Registry]

To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors

NCT ID: NCT05019677 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable advanced Biliary Tract Carcinoma (BTC).

NCT ID: NCT04546828 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

1. Phase of Development: II 2. Patient Population: Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma 3. Estimated Number of Patients: 34 patients 4. Primary Objective: To assess the resetability of neoadjuvant chemotherapy including gemcitabine, cisplatin, and nab-paclitaxel for resectable oncologically high-risk intrahepatic cholangiocarcinoma that is treated with surgical resection. Thus, the primary aim is to increase R0 resection rate via completion of all treatment 5. Secondary Objectives: 1) To assess the radiological response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) 2) To determine the overall resection rate 3) To determine recurrence-free survival (RFS) 4) To identify patients' overall survival (OS) rate. 5) Saftey and tolerability 6.Exploratory Endpoint : QoL analysis via EORTC QLO C-30

NCT ID: NCT04511793 Withdrawn - Liver Cancer Clinical Trials

Hepatic Artery Infusion (HAI) Program at Duke University

Start date: December 11, 2020
Phase: N/A
Study type: Interventional

The Duke HAI program was implemented in November 2018 and treated 30 patients in its first 17 months using the Medtronic Synchromed II device (only commercially available device suitable for HAI for cancer patients). The Duke HAI program has demonstrated safety of HAI with an overall complication rate was 19%, similar to prior published data, with all but one complication (extrahepatic perfusion) salvaged. The Investigator has also demonstrated feasibility and efficacy of a new HAI program, with 95% of patients initiating therapy with promising hepatic response and disease control rates. This protocol will enable the team to continue this program. All eligible patients will receive the synchromed II pump with a Codman catheter and chemotherapy including FUDR, dexamethasone and heparin. Systemic chemotherapy will be given per standard of care.

NCT ID: NCT04479904 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Start date: August 10, 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, multi-center Phase II clinical trial intended to observe and evaluate the efficacy and safety of famitinib malate in treating iCCA(Intrahepatic Cholangiocarcinoma ) patients with FGFR2 genetic aberrations who failed first-line therapy.

NCT ID: NCT03801499 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lenvatinib for patients with unresectable intrahepatic cholangiocarcinoma

NCT ID: NCT03081039 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

Start date: August 21, 2017
Phase: Phase 3
Study type: Interventional

Compare the efficacy of adjuvant chemotherapy with Cisplatin or Carboplatin and Gemcitabine versus Gemcitabine in patients with resected or ablated intra-hepatic cholangiocarcinoma.

NCT ID: NCT01775280 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Response of Hepatic Tumors to Radioembolization

RESRAD
Start date: October 2012
Phase: Phase 2
Study type: Interventional

The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis. Patients are not a candidates for liver transplantation and have only limited extrahepatic disease. All patients are treated with radioembolization. Primary endpoint is the percentage of patients that can be downstaged to resectability. Secondary endpoints are radiologic response to radioembolization,tissue response to radiomembolization and systemic immune response and intra-tumoral T-cell response to radioembolization. - Trial with radiotherapy